{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:11Z","timestamp":1791195671901,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00415-019-09296-y","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T09:00:36Z","timestamp":1553677236000},"page":"1596-1600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rituximab as induction therapy in refractory myasthenia gravis: 18\u00a0month follow-up study"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-0904","authenticated-orcid":false,"given":"Nishita","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"10","key":"9296_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"18","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 18(10):46","journal-title":"BMC Neurol"},{"issue":"23","key":"9296_CR2","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","volume":"70","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC (2008) Invited article: inhibition of B cell functions: implications for neurology. Neurology. 70(23):2252\u20132260","journal-title":"Neurology."},{"issue":"2","key":"9296_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56(2):185\u2013196","journal-title":"Muscle Nerve"},{"issue":"4","key":"9296_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 87(4):419\u2013425","journal-title":"Neurology."},{"issue":"369","key":"9296_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","volume":"15","author":"L Gotterer","year":"2016","unstructured":"Gotterer L, Li Y (2016) Maintenance immunosuppression in myasthenia gravis. J Neurol Sci 15(369):294\u2013302","journal-title":"J Neurol Sci"},{"issue":"4","key":"9296_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI (2014) Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 15(4):167\u2013178","journal-title":"J Clin Neuromuscul Dis."},{"issue":"9","key":"9296_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol Off J Eur Soc Med Oncol 9(9):995\u20131001","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"9296_CR8","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1212\/NXI.0000000000000077","volume":"2","author":"JT Guptill","year":"2015","unstructured":"Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM et al (2015) Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflammation 2(2):e77","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"772","key":"9296_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","volume":"66","author":"V Fonseca","year":"1990","unstructured":"Fonseca V, Havard CW (1990) Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J 66(772):102\u2013105","journal-title":"Postgrad Med J"},{"issue":"12","key":"9296_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S et al, REGAIN Study Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16(12):976\u2013986. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol."}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09296-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09296-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09296-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:09:24Z","timestamp":1585181364000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09296-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["9296"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09296-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"17 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest in submission of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by an ethics committee and\/or follows the tenants of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all the patients which should be included in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}